

## Alkynylation of Thiolactams. New Synthesis of $\alpha$ -Substituted Pyrrolidine and Piperidine Alkaloids

Hiroki Takahata,\* Koichi Takahashi,† Eng-Chi Wang, and Takao Yamazaki

Faculty of Pharmaceutical Sciences, Toyama Medical & Pharmaceutical University, 2630 Sugitani, Toyama 930-01, Japan

Alkynylation of *S*-alkylthioamidium salts of thiolactams with lithium acetylides followed by reduction with  $\text{LiAlH}_4$  provided  $\alpha$ -alkynylazacycloalkanes, which on reduction, or hydroboration followed by oxidation, gave  $\alpha$ -substituted pyrrolidine and piperidine alkaloids.


The development of functionalization methods for azacycloalkanes such as pyrrolidines, piperidines, and perhydroazepines is of great importance in the synthesis of naturally occurring alkaloids.<sup>1</sup> In connection with our studies on the utilization of the thioamide group in organic synthesis,<sup>2</sup> we describe the alkynylation of thiolactams, and subsequent manipulation leading to  $\alpha$ -substituted pyrrolidine and piperidine alkaloids.

The thioamide group has increasingly been recognized as a useful synthon in organic synthesis. Recently, the attack of organolithium reagents upon the carbon-sulphur double bond of thioamides has been explored.<sup>3</sup> Unfortunately, initial attempts at alkynylation of pyrrolidine-2-thione by treatment with lithium acetylides were unsuccessful. Previously, we described the carbon-carbon bond forming reaction of *S*-alkylthioamidium salts with malononitrile.<sup>4</sup> Here we describe the reaction<sup>5</sup> of *S*-alkylthioamidium salts, prepared from thiolactams by treatment with methyl iodide, with lithium acetylide, followed by reduction with lithium aluminium hydride ( $\text{LiAlH}_4$ ) to give  $\alpha$ -alkynylazacycloalkanes.

Thus, *S*-methylthioamidium salts (**I**), generated *in situ* from thiolactams (**1**)–(**3**) and methyl iodide in tetrahydrofuran (THF) at room temperature for 8 h, were treated with a lithium acetylide (**6**)–(**8**) at  $-78^\circ\text{C}$ . The resulting adducts (**II**) were then treated with  $\text{LiAlH}_4$  at  $-78^\circ\text{C}$  followed by warming to  $-20^\circ\text{C}$  to give the  $\alpha$ -alkynylazacycloalkanes (**10**)–(**17**) in moderate yields (Table, entries 1–8). Similarly, the  $\alpha$ -alkynylazacycloalkanes (**18**)–(**22**) were obtained from *N*-benzylthiolactams (**4**) and (**5**) (Table, entries 9–13).

Our attention was focussed on the synthesis of pyrrolidine and piperidine alkaloids by the elaboration (reduction or hydroboration) of the acetylene function. Hydrogenation of piperidinylacetylene (**17**) in the presence of palladium hydroxide [ $\text{Pd}(\text{OH})_2$ ] in methanol afforded ( $\pm$ )-*N*-methylconiine<sup>‡</sup> (**23**) quantitatively. Under the same conditions the *N*-benzyl derivative (**21**) underwent both reduction and hydrogenolysis<sup>6</sup> to provide ( $\pm$ )-coniine (**24**)<sup>‡</sup> quantitatively.

Hydroboration-oxidation of acetylenes is an effective procedure for regioselective ketone synthesis. However, to our knowledge, the hydroboration of acetylenic amines has scarcely been studied.<sup>7</sup> Monohydroboration of piperidinylacetylene (**17**) with bis(1,2-dimethylpropyl)borane<sup>§</sup> in THF at  $0^\circ\text{C}$  followed by oxidative work-up proceeded in a regioselective manner,



**Table.** Isolated yields of  $\alpha$ -alkynylazacycloalkanes from thiolactams (three-steps sequence)


Entry	Product	$\text{R}^1$	$\text{R}^2$	$n$	Yield (%)
1	(10)	Me	Ph	1	70
2	(11)	Me	Ph	2	67
3	(12)	Me	Ph	3	80
4	(13)	Me	$n\text{-C}_5\text{H}_{11}$	1	71
5	(14)	Me	$n\text{-C}_5\text{H}_{11}$	2	74
6	(15)	Me	$n\text{-C}_5\text{H}_{11}$	3	55
7	(16)	Me	Me	1	61
8	(17)	Me	Me	2	85
9	(18)	$\text{CH}_2\text{Ph}$	Ph	1	78
10	(19)	$\text{CH}_2\text{Ph}$	$n\text{-C}_5\text{H}_{11}$	1	67
11	(20)	$\text{CH}_2\text{Ph}$	Me	1	66
12	(21)	$\text{CH}_2\text{Ph}$	Me	2	65
13	(22)	$\text{CH}_2\text{Ph}$	TMS	1	80

with ketone formation at the less hindered carbon atom of the triple bond to give ( $\pm$ )-*N*-methylpelletierine (**25**) as a major product (50% yield), and its regioisomer (**26**) (14%). However, the regioselectivity (3.5:1) is not high compared with that (91:9) for the hydroboration of cyclohexylethyne.<sup>8</sup> This somewhat low regioselectivity may be due to co-ordination of the boron of the bis(1,2-dimethylpropyl)borane with the amine of the piperidine

† Visiting scientist from Tateyama Kasei Co. Ltd., Kosugi, Toyama, Japan, 1987–1988.

‡ Melting points of derivatives of these compounds were consistent with those described in the literature; see Experimental section.

§ Although treatment of (**17**) with 9-borabicyclo[3.3.1]nonane caused no reaction at room temperature, refluxing in THF provided (**25**) (34%) and (**26**) (33%) with no regioselectivity.



Scheme. (i)  $\text{Pd}(\text{OH})_2, \text{H}_2$ ; (ii) 1. bis(1,2-dimethylpropyl)borane, 2.  $\text{H}_2\text{O}_2/\text{NaOH}$

as in (27). Similarly, ( $\pm$ )-sedaminone (28)\* was obtained from (11) (50% yield), together with its regioisomer (29) (18%). On the other hand, hydroboration of the pyrrolidinylacetylene (16) showed higher regioselectivity than the piperidinyl analogue (17), providing ( $\pm$ )-hygrine (30) (54%) on oxidation. Similarly, the reaction of (20) proceeded regiospecifically to afford only (31), in 52% yield. This suggested that co-ordination of the boron of bis(1,2-dimethylpropyl)borane with the pyrrolidine nitrogen was difficult, presumably due to steric hindrance between the nitrogen substituent and the dialkyl group of the diborane.

In summary, the present study provides a convenient and simple procedure for the synthesis of  $\alpha$ -alkynylazacycloalkanes, which are transformed into  $\alpha$ -substituted pyrrolidine and piperidine alkaloids. This method should be applicable to the synthesis of many kinds of  $\alpha, \alpha'$ -disubstituted pyrrolidine and piperidine alkaloids<sup>10</sup> such as ant venom, and its application is now in progress.

## Experimental

M.p.s and b.p.s are uncorrected. M.p.s were measured with a Yanaco micro melting point apparatus and b.p.s were measured with a Buchi Kugelrohr apparatus. I.r. spectra were determined

with a JASCO A-102 spectrophotometer.  $^1\text{H}$  N.m.r. spectra were run on a JEOL PMX-60 (60 MHz) or JX-270 (270 MHz) spectrometer using  $\text{CDCl}_3$  as a solvent. Mass spectra were measured with a JEOL JMS-D200 spectrometer.

*General Procedure for Preparation of  $\alpha$ -Alkynylazacycloalkanes (10–22).*—A mixture of thiolactam (1)–(5) (5 mmol) and iodomethane (8 mmol) in THF (10 ml) was stirred at room temperature for 6 h under argon. The reaction mixture was cooled  $-78^\circ\text{C}$ , and to it was added a solution of lithium acetylide (6)–(9), prepared by the dropwise addition of butyllithium (1.6M in hexane, 3.75 ml, 6 mmol) to acetylene (6 mmol) in THF (5 ml) at  $-78^\circ\text{C}$ . The mixture was then allowed to warm to  $-20^\circ\text{C}$  over 2 h when  $\text{LiAlH}_4$  (500 mg, 13 mmol) at the same temperature was added. The mixture was stirred for a further hour at  $-10^\circ\text{C}$  when 10% aqueous sodium hydroxide (10 ml) was added to it; the mixture was then extracted with ethyl acetate. The combined organic extracts were washed with brine, dried ( $\text{MgSO}_4$ ), and evaporated under reduced pressure. Bulb-to-bulb distillation of the crude product using Kugelrohr apparatus yielded the  $\alpha$ -azacycloalkanes (10)–(22) (see Table).

1-(1-Methylpyrrolidin-2-yl)-2-phenylacetylene (10). B.p.  $72\text{--}79^\circ\text{C}$  at 0.5 mmHg (Found: C, 82.3; H, 8.1; N, 7.5.  $\text{C}_{13}\text{H}_{15}\text{N}$  requires C, 82.5; H, 8.2; N, 7.6%);  $\nu_{\text{max}}$ (neat) 2 200 and 1 595  $\text{cm}^{-1}$ ;  $\delta_{\text{H}}(\text{CDCl}_3)$  1.47–3.14 (m, 6 H), 2.50 (s, 3 H, NMe), 3.14–3.47 (m, 1 H, NCH), and 7.00–7.57 (m, 5 H, Ph).

1-(1-Methylpiperidin-2-yl)-2-phenylacetylene (11). B.p.  $82\text{--}87^\circ\text{C}$  at 0.5 mmHg (Found: C, 84.2; H, 8.6; N, 6.8.  $\text{C}_{14}\text{H}_{17}\text{N}$  requires C, 84.4; H, 8.6; N, 7.0%);  $\nu_{\text{max}}$ (neat) 2 200 and 1 595  $\text{cm}^{-1}$ ;  $\delta_{\text{H}}(\text{CDCl}_3)$  1.13–2.10 (m, 6 H), 2.10–2.90 (m, 2 H), 2.24 (s, 3 H, NMe), 3.54 (t,  $J$  4 Hz, 1 H, NCH), and 7.10–7.60 (m, 5 H, Ph).

1-(1-Methylperhydroazepin-2-yl)-2-phenylacetylene (12). B.p.  $90\text{--}95^\circ\text{C}$  at 0.5 mmHg (Found: C, 84.8; H, 8.7; N, 6.3.  $\text{C}_{15}\text{H}_{19}\text{N}$  requires C, 84.45; H, 9.0; N, 6.6%);  $\nu_{\text{max}}$ (neat) 2 200 and 1 595  $\text{cm}^{-1}$ ;  $\delta_{\text{H}}(\text{CDCl}_3)$  1.50–2.27 (m, 8 H), 2.27–3.00 (m, 2 H, NCH<sub>2</sub>), 2.50 (s, 3 H, NMe), 3.67–3.97 (m, 1 H, NCH), and 7.13–7.63 (m, 5 H, Ph).

1-(1-Methylpyrrolidin-2-yl)hept-1-yne (13). B.p.  $54\text{--}58^\circ\text{C}$  at 0.6 mmHg (Found: C, 80.0; H, 11.8; N, 7.5.  $\text{C}_{12}\text{H}_{21}\text{N}$  requires C, 80.4; H, 11.8; N, 7.8%);  $\nu_{\text{max}}$ (neat) 2 220  $\text{cm}^{-1}$ ;  $\delta_{\text{H}}(\text{CDCl}_3)$  0.60 (m, 3 H, Me), 1.03–2.50 (m, 14 H), 2.37 (s, 3 H, NMe), and 2.50–3.57 (m, 1 H, NCH).

1-(1-Methylpiperidin-2-yl)hept-1-yne (14). B.p.  $59\text{--}62^\circ\text{C}$  at 0.5 mmHg (Found: C, 80.5; H, 12.1; N, 7.0.  $\text{C}_{13}\text{H}_{23}\text{N}$  requires C, 80.8; H, 12.0; N, 7.25%);  $\nu_{\text{max}}$ (neat) 2 225  $\text{cm}^{-1}$ ;  $\delta_{\text{H}}(\text{CDCl}_3)$  0.67–1.04 (m, 3 H, Me), 1.04–2.63 (m, 16 H), 2.37 (s, 3 H, NMe), and 3.00–3.38 (m, 1 H, NCH).

1-(1-Methylperhydroazepin-2-yl)hept-1-yne (15). B.p.  $68\text{--}70^\circ\text{C}$  at 0.5 mmHg (Found: C, 79.6; H, 12.15; N, 6.3.  $\text{C}_{14}\text{H}_{25}\text{N}$  requires C, 81.1; H, 12.15; N, 6.8%);  $\nu_{\text{max}}$ (neat) 2 200  $\text{cm}^{-1}$ ;  $\delta_{\text{H}}(\text{CDCl}_3)$  0.60–1.04 (m, 3 H, Me), 1.04–2.80 (m, 18 H), 2.40 (s, 3 H, Me), and 3.33–3.77 (m, 1 H, NCH).

1-(1-Methylpyrrolidin-2-yl)prop-1-yne (16). B.p.  $68\text{--}71^\circ\text{C}$  at 17 mmHg (Found:  $M^+$ , 123.1049.  $\text{C}_8\text{H}_{13}\text{N}$  requires  $M$ , 123.1047);  $\nu_{\text{max}}$ (neat) 2 230  $\text{cm}^{-1}$ ;  $\delta_{\text{H}}(\text{CDCl}_3)$  1.60–2.70 (m, 5 H), 1.85 (d,  $J$  2 Hz, 3 H, Me), 2.41 (s, 3 H, NMe), and 2.70–3.30 (m, 1 H, NCH).

1-(1-Methylpiperidin-2-yl)prop-1-yne (17). B.p.  $64\text{--}67^\circ\text{C}$  at 15 mmHg (Found:  $M^+$ , 137.1202.  $\text{C}_9\text{H}_{15}\text{N}$  requires  $M$ , 137.1203);  $\nu_{\text{max}}$ (neat) 2 230  $\text{cm}^{-1}$ ;  $\delta_{\text{H}}(\text{CDCl}_3)$  1.10–2.00 (m, 6 H), 1.85 (d,  $J$  2 Hz, 3 H, CH<sub>2</sub>), 2.00–3.00 (m, 2 H, NCH<sub>2</sub>), 2.83 (s, 3 H, NMe), and 3.00–3.33 (m, 1 H, NCH).

1-(1-Benzylpyrrolidin-2-yl)-2-phenylacetylene (18). B.p.  $122\text{--}128^\circ\text{C}$  at 0.4 mmHg (Found: C, 87.5; H, 7.3; N, 5.5.  $\text{C}_{19}\text{H}_{19}\text{N}$  requires C, 87.3; H, 7.3; N, 5.4%);  $\nu_{\text{max}}$ (neat) 2 200 and 1 595  $\text{cm}^{-1}$ ;  $\delta_{\text{H}}(\text{CDCl}_3)$  1.57–3.00 (m, 6 H), 3.60 and 4.08 (ABq,  $J$  13 Hz, 2 H, CH<sub>2</sub>Ph), 3.62 (m, 1 H, NCH), and 7.16–7.63 (m, 10 H, 2Ph).

\* ( $\pm$ )-Sedaminone has previously been reduced to ( $\pm$ )-sedamine.<sup>9</sup>

1-(1-Benzylpyrrolidin-2-yl)hept-1-yne (**19**). B.p. 94–98 °C at 0.5 mmHg (Found: C, 84.8; H, 9.9; N, 5.2. C<sub>18</sub>H<sub>25</sub>N requires C, 84.65; H, 9.9; N, 5.5%);  $\nu_{\max}$ (neat) 2 210 and 1 600 cm<sup>-1</sup>;  $\delta_{\text{H}}$ (CDCl<sub>3</sub>) 0.64–1.10 (m, 3 H, Me), 1.10–3.33 (m, 14 H), 3.33–3.50 (m, 1 H, NCH), 3.47, 4.01 (ABq, *J* 13 Hz, 2 H, CH<sub>2</sub>Ph), and 7.30 (s, 5 H, Ph).

1-(1-Benzylpyrrolidin-2-yl)prop-1-yne (**20**). B.p. 73–76 °C at 0.15 mmHg (Found: C, 83.3; H, 8.3; N, 7.1. C<sub>14</sub>H<sub>17</sub>N·0.1H<sub>2</sub>O requires C, 83.6; H, 8.6; N, 7.0%; Found: *M*<sup>+</sup>, 199.1347. C<sub>14</sub>H<sub>17</sub>N requires *M*, 199.1359);  $\nu_{\max}$ (neat) 2 225 and 1 600 cm<sup>-1</sup>;  $\delta_{\text{H}}$ (CDCl<sub>3</sub>) 1.50–3.07 (m, 6 H), 1.87 (d, *J* 2 Hz, 3 H, Me), 3.07–3.50 (m, 1 H, NCH), 3.45, 4.05 (ABq, *J* 13 Hz, 2 H, CH<sub>2</sub>Ph), and 7.32 (s, 5 H, Ph).

1-(1-Benzylpiperidin-2-yl)prop-1-yne (**21**). B.p. 88–89 °C at 0.3 mmHg (Found: C, 84.6; H, 8.9; N, 6.5. C<sub>15</sub>H<sub>19</sub>N requires C, 84.45; H, 9.0; N, 6.6%);  $\nu_{\max}$ (neat) 2 225 and 1 600 cm<sup>-1</sup>;  $\delta_{\text{H}}$ (CDCl<sub>3</sub>) 1.00–2.10 (m, 6 H), 1.92 (d, *J* 2 Hz, 3 H, Me), 2.10–3.20 (m, 2 H, NCH<sub>2</sub>), 3.20–3.80 (m, 1 H, NCH), 3.51, 3.77 (ABq, *J* 13 Hz, 2 H, CH<sub>2</sub>Ph), and 7.10–7.54 (m, 5 H, Ph).

1-(1-Benzylpyrrolidin-2-yl)-2-trimethylsilylacetylene (**22**). B.p. 86–91 °C at 0.4 mmHg (Found: C, 74.9; H, 9.1; N, 5.6. C<sub>16</sub>H<sub>23</sub>NSi requires C, 74.6; H, 9.0; N, 5.4%);  $\nu_{\max}$ (neat) 2 150 and 1 600 cm<sup>-1</sup>;  $\delta_{\text{H}}$ (CDCl<sub>3</sub>) 0.22 (s, 9 H, SiMe<sub>3</sub>), 1.53–2.23 (m, 4 H), 2.23–2.87 (m, 2 H, NCH<sub>2</sub>), 3.16–3.20 (m, 1 H, NCH), 3.54, 4.05 (ABq, *J* 13 Hz, 2 H, CH<sub>2</sub>Ph), and 7.37 (s, 5 H, Ph).

(±)-*N*-Methylconiine (**23**).—A mixture of (**17**) (45 mg) and Pd(OH)<sub>2</sub><sup>12</sup> (14 mg) in methanol (3 ml) was stirred under hydrogen (1 atm) for 2.5 h. Filtration followed by washing of the residue with methanol and evaporation of the solvent yielded (**23**) (58 mg, 100%) as an oil;  $\delta_{\text{H}}$ (CDCl<sub>3</sub>) 0.67–1.04 (m, 3 H, Me), 1.04–2.33 (m, 12 H), 2.27 (s, 3 H, NMe), and 2.60–3.10 (m, 1 H, NCH); hydrochloride salt, m.p. 169–170 °C (acetone) (lit.<sup>12</sup> 168–168.5 °C) (Found: C, 59.9; H, 11.2; N, 7.8. Calc. for C<sub>9</sub>H<sub>20</sub>ClN·0.1H<sub>2</sub>O: C, 60.2; H, 11.25; N, 7.8%).

(±)-*Coniine* (**24**).—A mixture of (**21**) (108 mg) and Pd(OH)<sub>2</sub> (10 mg) in methanol (3 ml) was stirred under hydrogen (1 atm) for 7 h, then worked-up by the method described for (**23**) to give (**24**) (81 mg, 100%) as an oil;  $\nu_{\max}$  3 300 and 1 650 cm<sup>-1</sup>;  $\delta_{\text{H}}$ (CDCl<sub>3</sub>) 0.85 (br t, *J* 6 Hz, 3 H), and 2.00–3.30 (m, 3 H); i.r. and <sup>1</sup>H n.m.r. spectra were identical with those described in the literature.<sup>13</sup> The hydrochloride salt was crystallised from acetone–methanol, m.p. 219–220 °C (lit.<sup>12</sup> 216–217 °C) (Found: C, 58.6; H, 11.1; N, 8.6. Calc. for C<sub>8</sub>H<sub>18</sub>ClN: C, 58.7; H, 11.1; N, 8.55%).

*General Procedure for Monohydroboration and Oxidation of  $\alpha$ -Alkynylazacycloalkanes.*—To a stirred solution of bis(1,2-dimethylpropyl)borane (0.5 mmol), prepared from borane–THF complex (1.0M, 1.5 ml) and 2-methylbut-2-ene (3 mmol, 0.32 ml) by the method of H. C. Brown,<sup>14</sup> was added a solution of  $\alpha$ -alkynylazacycloalkane (0.5 mmol) in THF (2 ml) at 0 °C. The mixture was kept in a refrigerator (5 °C) overnight after which it was quenched with 6M aqueous NaOH (0.3 ml) and 30% aqueous H<sub>2</sub>O<sub>2</sub> (0.6 ml) at 0 °C; it was then stirred for an additional hour at room temperature. The reaction mixture was cooled to 0 °C, 10% hydrochloric acid (2 ml) was added and it was then stirred for 30 min at room temperature and washed with diethyl ether. The aqueous layer was made alkaline with K<sub>2</sub>CO<sub>3</sub> and extracted with diethyl ether. The extract was dried (K<sub>2</sub>CO<sub>3</sub>) and concentrated, and the residue separated by alumina column chromatography (hexane–ethyl acetate, 30:1) to give the amino ketones.

(±)-*N*-Methylpelletierine (**25**) (50%). B.p. 67–69 °C at 15 mmHg (Found: *M*<sup>+</sup>, 155.1288. C<sub>9</sub>H<sub>17</sub>NO requires *M*, 155.1309);  $\nu_{\max}$ (neat) 1 710 cm<sup>-1</sup>;  $\delta_{\text{H}}$ (CDCl<sub>3</sub>) 1.19–1.40 (m, 2 H), 1.47–1.68 (m, 4 H), 2.18 (s, 3 H, Me), 2.21 (s, 3 H, NMe),

2.11–2.45 (m, 2 H), 2.52–2.59 (m, 1 H), and 2.75–2.83 (m, 2 H). The hydrochloride salt was crystallised from ethyl acetate, m.p. 161.5–162.5 °C (lit.<sup>15</sup> 158–159 °C) (Found: C, 56.4; H, 9.4; N, 7.3. Calc. for C<sub>9</sub>H<sub>18</sub>ClNO: C, 56.4; H, 9.5; N, 7.3%).

*Ethyl 1-methylpiperidin-2-yl ketone* (**26**) (14%). B.p. 65–67 °C at 15 mmHg (Found: *M*<sup>+</sup>, 155.1303. C<sub>9</sub>H<sub>17</sub>NO requires *M*, 155.1305);  $\nu_{\max}$ (neat) 1 710 cm<sup>-1</sup>;  $\delta_{\text{H}}$ (CDCl<sub>3</sub>) 1.06 (t, *J* 7 Hz, 3 H, Me), 1.18–2.69 (m, 10 H), 2.13 (s, 3 H, NMe), and 2.90–2.95 (m, 1 H, NCH).

(±)-*Sedaminone* (**28**). 50%; b.p. 92–93 °C at 0.15 mmHg (lit.<sup>16</sup> 135–136 °C at 1 mmHg) (Found: *M*<sup>+</sup>, 217.1437. Calc. for C<sub>14</sub>H<sub>19</sub>NO: *M*, 217.1465);  $\nu_{\max}$ (neat) 1 680 and 1 595 cm<sup>-1</sup>;  $\delta_{\text{H}}$ (CDCl<sub>3</sub>) 1.00–2.53 (m, 7 H), 2.32 (s, 3 H, NMe), 2.53–3.92 (m, 4 H), 7.30–8.20 (m, 5 H, Ph). Picrate, m.p. 159.5–161 °C (lit.<sup>16</sup> 159–160 °C) (Found: C, 53.7; H, 5.0; N, 12.75. Calc. for C<sub>20</sub>H<sub>22</sub>N<sub>4</sub>O<sub>8</sub>: C, 53.8; H, 5.0; N, 12.55%).

*Benzyl 1-methylpiperidin-2-yl ketone* (**29**) (18%). B.p. 87–90 °C at 0.15 mmHg (Found: C, 77.0; H, 8.85; N, 6.6. C<sub>14</sub>H<sub>19</sub>NO requires C, 77.4; H, 8.8; N, 6.45%);  $\nu_{\max}$ (neat) 1 715 and 1 600 cm<sup>-1</sup>;  $\delta_{\text{H}}$ (CDCl<sub>3</sub>) 0.90–2.33 (m, 6 H), 2.13 (s, 3 H, NMe), 2.47–3.27 (m, 3 H, NCH and NCH<sub>2</sub>), 3.83 (s, 2 H, CH<sub>2</sub>Ph), and 7.34 (s, 5 H, Ph).

(±)-*Hygrine* (**30**) (54%). B.p. 71.5–75 °C at 15 mmHg;  $\nu_{\max}$ (neat) 1 710 cm<sup>-1</sup>;  $\delta_{\text{H}}$ (CDCl<sub>3</sub>) 1.00–2.73 (m, 6 H), 2.13 (s, 3 H), 2.26 (s, 3 H), and 2.73–3.53 (m, 3 H). I.r. and <sup>1</sup>H n.m.r. spectra were identical with those described in the literature.<sup>17</sup> Picrate, m.p. 151–153 °C (ethanol) (lit.<sup>18</sup> 153.5–155 °C) (Found: C, 45.4; H, 4.9; N, 15.4. Calc. for C<sub>14</sub>H<sub>18</sub>N<sub>4</sub>O<sub>8</sub>: C, 45.4; H, 4.9; N, 15.1%).

(±)-*N*-Benzylhygrine (**31**) (52%). B.p. 87.5–91.5 °C at 0.15 mmHg (Found: C, 77.6; H, 8.7; N, 6.2. C<sub>14</sub>H<sub>19</sub>NO requires C, 77.4; H, 8.8; N, 6.45%);  $\nu_{\max}$ (neat) 1 710 and 1 600 cm<sup>-1</sup>;  $\delta_{\text{H}}$ (CDCl<sub>3</sub>) 1.00–3.20 (m, 9 H), 2.17 (s, 3 H, Me), 3.42, 3.99 (ABq, *J* 13 Hz, 2 H, CH<sub>2</sub>Ph), and 7.38 (s, 5 H, Ph).

## Acknowledgements

We gratefully acknowledge the partial financial assistance of The Research Foundation for Pharmaceutical Sciences for this study.

## References

- (a) K. Shiosaki and H. Rapoport, *J. Org. Chem.*, 1985, **50**, 1229; (b) P. Q. Huang, S. Arseniyadis, and H.-P. Husson, *Tetrahedron Lett.*, 1987, **28**, 547; (c) M. Yamaguchi and I. Hirao, *ibid.*, 1983, **23**, 1719.
- For reviews see (a) H. Takahata and T. Yamazaki, *J. Syn. Org. Chem. Jpn.*, 1987, **45**, 686; (b) *Heterocycles*, 1988, **27**, 1953.
- Y. Tomimaga, S. Kohra, and A. Hosomi, *Tetrahedron Lett.*, 1987, **28**, 1529.
- H. Takahata, E.-C. Wang, T. Nakajima, and T. Yamazaki, *Chem. Pharm. Bull.*, 1987, **35**, 3139.
- T. Yamaguchi, Y. Shimizu, and T. Suzuki, *Chem. Ind.*, 1972, 380.
- K. Yoshida, S. Nakajima, T. Wakamatsu, Y. Ban, and M. Shibasaki, *Heterocycles*, 1988, **27**, 1167.
- The hydroboration of olefinic amines has been reported: (a) A. Dicko, M. Montury, and M. Baboulene, *Tetrahedron Lett.*, 1987, **28**, 6041; (b) M. M. B. Nemia, J. Lee, and M. M. Joullie, *Synth. Commun.*, 1983, **13**, 1117; (c) M. Baboulene, J.-L. Torregrosa, V. Speziale, and A. Lattes, *Bull. Soc. Chim. Fr.*, 1980, 565.
- G. Zweifel, G. M. Clark, and N. Polston, *J. Am. Chem. Soc.*, 1971, **93**, 3395.
- H. C. Beyerman, W. Eveleens, and Y. M. F. Muller, *Recl. Trav. Chem.*, 1956, **75**, 63.
- (a) G. Strunz and J. Findlay, in 'The Alkaloids,' A. Brossi, (ed.), Academic Press, New York, 1986, vol. 26, pp. 89–183; (b) G. Massiot and C. Delaude, *ibid.*, 1986, vol. 27, pp. 269–322; (c) A. Numata and T. Ibuka, *ibid.*, 1987, vol. 31, pp. 193–315.
- S. Nishimura, M. Shimahara, and M. Siota, *J. Org. Chem.*, 1966, **31**, 2394.

- 12 'Dictionary of Organic Compounds,' J. Buckingham (ed.), Chapman and Hall, New York, 1982, vol. 5, p. 4800—4801.
- 13 K. Aketa, S. Terashima, and S. Yamada, *Chem. Pharm. Bull.*, 1976, **24**, 621.
- 14 H. C. Brown, 'Organic Synthesis *via* Boranes,' Wiley International, New York, 1975, p. 29—31.
- 15 E. Leistner and I. D. Spenser, *J. Am. Chem. Soc.*, 1973, **95**, 4715.
- 16 H. C. Beyerman and P. H. Enthoven, *Recl. Trav. Chim. Pays-Bas*, 1956, **75**, 82.
- 17 I. R. C. Bick, J. W. Gillard, and H. M. Leow, *Aust. J. Chem.*, 1979, **32**, 2523.
- 18 R. Ghirlando, A. S. Howard, R. B. Katz, and J. P. Michael, *Tetrahedron*, 1984, **40**, 2879.

*Received 4th October 1988; Paper 8/03953D*